Ibrutinib / Ibrutinib Capsules / Imbruvica (Everest)

🧬 Product Overview

Ibrutinib (Brand name: Imbruvica), also known as Ibrutinib, is the world’s first approved BTK inhibitor. By precisely targeting the BTK signaling pathway, it helps block the growth, spread, and survival of malignant tumor cells.

Due to its proven efficacy and relatively manageable side effect profile, Ibrutinib has become an important treatment option for various hematologic malignancies, especially for elderly patients or those unable to tolerate traditional chemotherapy.

✅ Approved Indications

Ibrutinib is currently approved for the treatment of:

• Mantle Cell Lymphoma (MCL) — for relapsed or refractory patients who have received at least one prior therapy
• Chronic Lymphocytic Leukemia (CLL) — including high-risk patients with 17p deletion
• Waldenström’s Macroglobulinemia (WM)

Many of these approvals were supported by strong overall response rate data, with ongoing long-term follow-up studies continuing worldwide.

🔬 Expanding Research Areas

In addition to currently approved uses, Ibrutinib is being actively studied in a range of additional hematologic diseases, including:

• Follicular Lymphoma (FL)
• Diffuse Large B-Cell Lymphoma (DLBCL)
• Small Lymphocytic Lymphoma (SLL)
• Marginal Zone Lymphoma (MZL)
• Multiple Myeloma (MM)
• Acute Lymphoblastic Leukemia (ALL)

Researchers are also exploring its potential in non-cancer conditions such as:

• Autoimmune diseases (including lupus and rheumatoid arthritis)
• Graft-versus-host disease (GVHD) and other rare complications

These studies may provide new therapeutic possibilities for future patients.

💡 Recommended Patient Groups

Ibrutinib may be particularly suitable for patients who:

• Are elderly or unable to tolerate intensive chemotherapy
• Have experienced relapse after previous treatment
• Carry high-risk genetic abnormalities such as 17p deletion or TP53 mutation

💊 Dosage and Administration

Take capsules with a full glass of water. Do not chew, crush, or open the capsules.

⚠️ Important Precautions

• Avoid grapefruit and grapefruit-containing products during treatment due to potential drug interactions
• Inform your healthcare provider if you are taking anticoagulants, antifungal medications, antibiotics, or other prescription drugs
• Seek medical attention promptly if you experience bleeding symptoms, fever, infection, irregular heartbeat, or blood pressure fluctuations

📦 Packaging Information

• 140 mg capsule formulation
• Bottle quantity may vary depending on packaging specifications and prescription requirements

🌍 Global Clinical Use

Ibrutinib was jointly developed by Johnson & Johnson (Janssen) and Pharmacyclics. Since receiving its first FDA approval in 2013, it has been widely used across the United States, Europe, Japan, Hong Kong, and many other regions.

Everest-manufactured versions are developed to match the reference formulation while offering improved affordability and accessibility for patients.

❤️ Patient Support Reminder

Treatment for hematologic cancers is often a long-term journey. As an oral targeted therapy, Ibrutinib offers convenient administration, clinically established efficacy, and relatively manageable treatment monitoring, providing patients with a more sustainable treatment option.

Patients are encouraged to use this medication under professional medical supervision and to undergo regular monitoring of blood counts, liver function, and kidney function to help ensure safe and effective treatment.